We are very pleased to announce that, effective August 24th, 2016 – IBA Molecular has entered into a “definitive agreement” with Mallinckrodt to acquire its global radiopharmaceutical division. The enlarged IBA Molecular will be able to leverage the strengths of both businesses to provide customers with the most reliable supply chain and an excellent, diverse product portfolio, with a comprehensive global footprint.
The transaction is subject to normal closing conditions and we are targeting completion in the first half of calendar 2017. Until the transaction is concluded, it will be business as usual for both companies and we will continue to operate as separate businesses. You will continue to work with the same people.
We are determined to ensure that you will receive the same high service level that you have been accustomed to receiving from us in the past and which has underpinned the success of both businesses up to now. As we embark on this exciting new journey, we look forward to sharing the considerable opportunities that lie ahead. Once the acquisition closes, we will provide you with more in-depth details. If you have any questions in the meantime, please feel free to contact us.
Thank you for your ongoing business, loyalty, and support over the past years. We are truly committed to providing the same high quality service that has become our trademark.
Chief Executive Officer
+ 33 (0)1 69 85 70 70